SW
CCCC icon

SVB Wealth’s C4 Therapeutics CCCC Stock Holding History

SVB Wealth’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,007
Closed -$31.4K – 938
2023
Q1 		$31.4K Hold
10,007
– – ﹤0.01% 988
2022
Q4 		$59K Hold
10,007
– – ﹤0.01% 1000
2022
Q3 		$88K Buy
+10,007
New +$104K ﹤0.01% 923

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

SVB Wealth's CCCC Position: Q2 2023 in Review

SVB Wealth sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 10,007 shares — an estimated $31.4K sold.

SVB Wealth first reported a position in CCCC in Q3 2022 and held it in 3 quarters. The position peaked at $88K in Q3 2022. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • SVB Wealth reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • SVB Wealth sold 10,007 C4 Therapeutics shares in Q2 2023, an estimated $31.4K.
  • SVB Wealth first reported a position in C4 Therapeutics in Q3 2022 and held it in 3 quarters.
  • SVB Wealth's C4 Therapeutics position peaked at $88K in Q3 2022.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on SVB Wealth's 13F filing for Q2 2023, filed 24 Jul 2023.